News about Global Pharma

Gland Pharma Gets FDA Approval for Phytonadione Injectable Emulsion

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vitamin KI1 Injectable Emulsion USP, 10 mg/mL, of Hospira, Inc.

Global Pharma | 16/12/2024 | By Aishwarya |  735

Neurocrine Biosciences Secures FDA Approval of CRENESSITY

CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction.

Global Pharma | 16/12/2024 | By Aishwarya |  217

Tanner Pharma to Expand Global Access of BOT and BAL with Agenus

Tanner Pharma will manage access to BOT/BAL for patients in geographies that allow named patient access to investigational medicines.

Global Pharma | 13/12/2024 | By Aishwarya |  347

aTyr Pharma Welcomes Eric Benevich to its Board of Directors

Benevich has served as Chief Commercial Officer of Neurocrine since May 2015 and is responsible for all aspects of commercial development, marketing, and sales of the Neurocrine product portfolio.

Global Pharma | 13/12/2024 | By Aishwarya |  348

AbbVie Announces Acquisition of Aliada Therapeutics

Aliada's lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, which is in development for the treatment of patients with Alzheimer's disease and is currently in a Phase 1 clinical trial.

Global Pharma | 13/12/2024 | By Aishwarya |  511

Abselion Secures EUR 6.6 Million in Series A Financing

Abselion will use the funds to drive the commercialisation and expand the capabilities of its Amperia system.

Global Pharma | 12/12/2024 | By Aishwarya |  251

Asahi Kasei Pharma Signs Exclusive License Deal for Anti-CX3CR1 Antibody

The anti-CX3CR1 antibody, currently in preclinical development, works by inhibiting CX3CR1, a receptor involved in immune cell migration to inflammatory sites.

Global Pharma | 12/12/2024 | By Aishwarya |  354

Endo Secures FDA Approval for its Manufacturing Facility in Indore

The Indore facility is designed specifically for aseptic manufacturing of sterile injectable products—a difficult and highly specialized production capability.

Global Pharma | 11/12/2024 | By Aishwarya |  882

Nona Biosciences, Kodiak Sciences to Power Next-Gen Antibody Therapies for Ophthalmic Diseases

The Harbour Mice platform generates fully human monoclonal antibodies in both the two heavy and two light chains (H2L2) format and the heavy chain-only (HCAb) format, eliminating the need for additional engineering or humanization.

Global Pharma | 11/12/2024 | By Aishwarya |  426

Skyhawk Gets Australian Regulatory Approval to Extend SKY-0515 Treatment Duration

HREC also agreed to the inclusion of Volumetric MRI (vMRI) measurements as an early exploratory endpoint in the trial.

Global Pharma | 11/12/2024 | By Aishwarya |  634